JP2010522227A5 - - Google Patents

Info

Publication number

JP2010522227A5

JP2010522227A5 JP2010500344A JP2010500344A JP2010522227A5 JP 2010522227 A5 JP2010522227 A5 JP 2010522227A5 JP 2010500344 A JP2010500344 A JP 2010500344A JP 2010500344 A JP2010500344 A JP 2010500344A JP 2010522227 A5 JP2010522227 A5 JP 2010522227A5

Authority

JP

Japan

Prior art keywords

pharmaceutically acceptable

compound

acceptable salt

hydrogen

formula

Prior art date

2008-03-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 18
• 150000003839 salts Chemical class 0.000 claims 15
• 229910052739 hydrogen Inorganic materials 0.000 claims 11
• 239000001257 hydrogen Substances 0.000 claims 11
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
• 150000002431 hydrogen Chemical class 0.000 claims 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
• 239000002671 adjuvant Substances 0.000 claims 2
• 239000003085 diluting agent Substances 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
• HCXBYIHIMJUDJQ-YUMQZZPRSA-N (1s,3s)-1-(aminomethyl)-3-methylcyclohexan-1-ol Chemical compound C[C@H]1CCC[C@@](O)(CN)C1 HCXBYIHIMJUDJQ-YUMQZZPRSA-N 0.000 claims 1
• OGZOWUDUUFGSIY-UHFFFAOYSA-N 2,6-dichloro-5-iodoquinoline Chemical compound IC1=C(Cl)C=CC2=NC(Cl)=CC=C21 OGZOWUDUUFGSIY-UHFFFAOYSA-N 0.000 claims 1
• HDDHLRKCWLHXTN-OPILKIMUSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-(3-hydroxy-3-methylpyrrolidin-1-yl)quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3CC(C)(O)CC3)=CC=C12 HDDHLRKCWLHXTN-OPILKIMUSA-N 0.000 claims 1
• BAHOQKHEWZJWME-WNSKOXEYSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-(4-hydroxypiperidin-1-yl)quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3CCC(O)CC3)=CC=C12 BAHOQKHEWZJWME-WNSKOXEYSA-N 0.000 claims 1
• GTFTZKPCYSYNOU-KIMHZCHSSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-[(3r)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3C[C@H](O)CC3)=CC=C12 GTFTZKPCYSYNOU-KIMHZCHSSA-N 0.000 claims 1
• GTFTZKPCYSYNOU-DFFLPILJSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-[(3s)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3C[C@@H](O)CC3)=CC=C12 GTFTZKPCYSYNOU-DFFLPILJSA-N 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 238000002360 preparation method Methods 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• BURJIEWNHIKROD-FWDYTFEUSA-N [[(2r,3r,4r,5s)-5-(6-aminopurin-9-yl)-4,5-dibenzoyl-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C([C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@]1(N1C=2N=CN=C(C=2N=C1)N)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 BURJIEWNHIKROD-FWDYTFEUSA-N 0.000 description 3
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
• 229960005542 ethidium bromide Drugs 0.000 description 2
• 108020003215 DNA Probes Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000004634 pharmacological analysis method Methods 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1